Activation and Deactivation of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine by Cytochrome P450 Enzymes and Flavin-Containing Monooxygenases in Common Marmosets (Callithrix jacchus)

Drug Metabolism and Disposition - Tập 43 Số 5 - Trang 735-742 - 2015
Shotaro Uehara1,2,3,4, Yasuhiro Uno1,2,3,4, Takashi Inoue1,2,3,4, Norie Murayama1,2,3,4, Makiko Shimizu1,2,3,4, Erika Sasaki1,2,3,4, Hiroshi Yamazaki1,2,3,4
1Department of Applied Developmental Biology, Central Institute for Experimental Animals, Kawasaki, Kanagawa, Japan (T.I., E.S.)
2Keio Advanced Research Center, Keio University, Minato-ku, Tokyo, Japan (E.S.)
3Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo, Japan (S.U., N.M., M.S., H.Y.)
4Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Wakayama, Japan (Y.U.)

Tóm tắt

Từ khóa


Tài liệu tham khảo

Abbott, 2003, Aspects of common marmoset basic biology and life history important for biomedical research, Comp Med, 53, 339

10.1016/j.pbb.2014.10.009

10.1371/journal.pone.0046371

10.1074/jbc.M112.402123

10.1212/WNL.35.7.949

10.1016/j.coviro.2012.02.007

Cashman, 1986, Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations, Mol Pharmacol, 29, 163

10.1016/0014-2999(90)90592-T

Chiba, 1985, Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Drug Metab Dispos, 13, 342

Coleman, 1996, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4—implications for susceptibility to Parkinson’s disease, J Pharmacol Exp Ther, 277, 685

10.1038/nm0697-671

10.1016/j.brainresbull.2005.08.005

Herraiz, 2013, Metabolite profile resulting from the activation/inactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-methyltetrahydro-β-carboline by oxidative enzymes, Biomed Res Int, 2013, 248608, 10.1155/2013/248608

10.1016/j.bcp.2004.03.018

Jenner, 2009, From the MPTP-treated primate to the treatment of motor complications in Parkinson’s disease, Parkinsonism Relat Disord, 15, S18, 10.1016/S1353-8020(09)70829-6

10.1093/toxsci/kfq374

Jones, 1986, Reactions of the 4a-hydroperoxide of liver microsomal flavin-containing monooxygenase with nucleophilic and electrophilic substrates, J Biol Chem, 261, 2553, 10.1016/S0021-9258(17)35823-4

10.1007/s00228-010-0876-4

Langston, 1983, Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, N Engl J Med, 309, 310, 10.1056/NEJM198308043090511

Mansfield, 2003, Marmoset models commonly used in biomedical research, Comp Med, 53, 383

10.1016/j.siny.2012.07.002

10.1371/journal.pone.0100936

10.1538/expanim.61.389

10.1124/jpet.111.185009

10.3109/00498254.2010.501118

10.3109/03602532.2010.549492

10.1016/j.bcp.2013.04.012

10.1124/dmd.110.033274

10.1124/dmd.114.059220

10.1006/prep.2001.1578

10.1016/j.bcp.2013.03.020

10.1016/j.bcp.2014.04.019

Yoshihara, 2000, Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in perfused rat liver: involvement of hepatic aldehyde oxidase as a detoxification enzyme, Drug Metab Dispos, 28, 538